Researchers have identified eight distinct genetic 'footprints' associated with approximately 85% of prostate cancers, a discovery that could significantly improve early detection and lead to more personalized treatment strategies. The findings, published in the journal Nature by the Pan Prostate Cancer Group (PPCG), offer new insights into the biological mechanisms driving the disease, potentially allowing for the identification of aggressive forms of cancer sooner.
Four of the identified genetic patterns were specifically linked to cancers that showed a greater likelihood of spreading beyond the prostate. Scientists described these as crucial new clues that could pave the way for enhanced diagnostic tests and earlier identification of high-risk cases. The study examined tumor samples from 959 men and revealed that some genetic footprints are also associated with factors like age and ancestry, noting patterns more prevalent in Black men.
Prostate cancer is a significant health concern, particularly in the UK, where it is the most common cancer in men, resulting in 63,000 cases and 12,000 deaths annually. Many diagnoses occur too late for effective treatment. Black men have a one in four lifetime risk, double that of the general population, and men with a family history of the disease face a similar risk.
"For many years we’ve known that prostate cancer is not a single disease," said Ros Eeles, professor of oncogenetics at The Institute of Cancer Research and a co-founder of the PPCG. "Two men may receive the same diagnosis but have cancers that develop and behave very differently, and we have not fully understood the biology behind those differences."
Experts believe this research brings the medical community closer to understanding distinct molecular forms of prostate cancer. The long-term goal, according to Eeles, is to ensure patients receive the most appropriate treatment based on their individual cancer's biology, moving away from a one-size-fits-all approach.
Professor Colin Cooper, professor of cancer genetics at the University of East Anglia and another co-founder of the PPCG, emphasized the collaborative nature of the study. "The scale of collaboration has helped uncover important new clues about the biological processes that drive prostate cancer and why some forms are more aggressive than others," he stated. He added that the findings contribute to building a clearer picture of why some cancers grow slowly while others become life-threatening.
Lead author Professor Joachim Weischenfeldt from the University of Copenhagen highlighted the clinical significance of these genetic markers. "It is remarkable how much clinical significance these genetic fingerprints appear to have," he said. "They can help distinguish between patients who are developing life-threatening cancer and those who are not." While further clinical studies are necessary before these findings can be applied in patient care, they represent a significant step toward understanding aggressive prostate cancer and developing personalized treatments.
Hayley Luxton from Prostate Cancer UK, which partly funded the study, noted that current methods make it difficult to determine which prostate cancers are likely to spread. "These findings from the Pan Prostate Cancer Group are hugely exciting and could lead to men getting the personalised treatment they need for their prostate cancer," she commented.